Sign In
Buy GNGBY
GETINGE AB UNSP ADR Earnings Calls
| Release date | Apr 21, 2026 |
| EPS estimate | - |
| EPS actual | $0.200 |
| Revenue estimate | 816.348M |
| Revenue actual | 785.683M |
| Revenue Surprise | -3.76% |
| Release date | Jan 27, 2026 |
| EPS estimate | - |
| EPS actual | $0.470 |
| Revenue estimate | 1.113B |
| Revenue actual | 1.102B |
| Revenue Surprise | -0.95% |
| Release date | Oct 21, 2025 |
| EPS estimate | - |
| EPS actual | $0.250 |
| Revenue estimate | - |
| Revenue actual | 864.317M |
| Release date | Jul 18, 2025 |
| EPS estimate | - |
| EPS actual | $0.230 |
| Revenue estimate | 833.311M |
| Revenue actual | 860.789M |
| Revenue Surprise | 3.30% |
Last 4 Quarters for GETINGE AB UNSP ADR
Below you can see how GNGBY performed 4 days prior and 4 days after releasing the earnings report. Also, you can see the pre-estimates and the actual earnings. This information can give you a slight idea of what you might expect for the next quarter's release.
| Release date | Jul 18, 2025 |
| Price on release | $20.66 |
| EPS estimate | - |
| EPS actual | $0.230 |
| Date | Price |
|---|---|
| Jul 14, 2025 | $19.53 |
| Jul 15, 2025 | $19.25 |
| Jul 16, 2025 | $19.20 |
| Jul 17, 2025 | $19.33 |
| Jul 18, 2025 | $20.66 |
| Jul 21, 2025 | $19.62 |
| Jul 22, 2025 | $19.85 |
| Jul 23, 2025 | $20.65 |
| Jul 24, 2025 | $20.95 |
| 4 days before | 5.79% |
| 4 days after | 1.41% |
| On release day | -5.03% |
| Change in period | 7.28% |
| Release date | Oct 21, 2025 |
| Price on release | $23.53 |
| EPS estimate | - |
| EPS actual | $0.250 |
| Date | Price |
|---|---|
| Oct 15, 2025 | $21.86 |
| Oct 16, 2025 | $22.59 |
| Oct 17, 2025 | $22.81 |
| Oct 20, 2025 | $22.96 |
| Oct 21, 2025 | $23.53 |
| Oct 22, 2025 | $23.70 |
| Oct 23, 2025 | $23.95 |
| Oct 24, 2025 | $23.66 |
| Oct 27, 2025 | $23.62 |
| 4 days before | 7.64% |
| 4 days after | 0.382% |
| On release day | 0.722% |
| Change in period | 8.05% |
| Release date | Jan 27, 2026 |
| Price on release | $22.55 |
| EPS estimate | - |
| EPS actual | $0.470 |
| Date | Price |
|---|---|
| Jan 21, 2026 | $22.79 |
| Jan 22, 2026 | $23.31 |
| Jan 23, 2026 | $23.56 |
| Jan 26, 2026 | $23.62 |
| Jan 27, 2026 | $22.55 |
| Jan 28, 2026 | $22.25 |
| Jan 29, 2026 | $22.25 |
| Jan 30, 2026 | $21.96 |
| Feb 02, 2026 | $21.92 |
| 4 days before | -1.05% |
| 4 days after | -2.79% |
| On release day | -1.35% |
| Change in period | -3.82% |
| Release date | Apr 21, 2026 |
| Price on release | $21.46 |
| EPS estimate | - |
| EPS actual | $0.200 |
| Date | Price |
|---|---|
| Apr 15, 2026 | $21.72 |
| Apr 16, 2026 | $21.89 |
| Apr 17, 2026 | $21.82 |
| Apr 20, 2026 | $21.73 |
| Apr 21, 2026 | $21.46 |
| Apr 22, 2026 | $21.56 |
| Apr 23, 2026 | $20.44 |
| Apr 24, 2026 | $20.69 |
| Apr 27, 2026 | $21.04 |
| 4 days before | -1.17% |
| 4 days after | -1.98% |
| On release day | 0.466% |
| Change in period | -3.13% |
GETINGE AB UNSP ADR Earnings Call Transcript Summary of Q1 2026
Getinge delivered a solid Q1 2026 with organic net sales growth of 0.8% and order intake up 3.9% organically. Growth was driven by Life Science and Surgical Workflows, while Acute Care Therapies was impacted by ventilator comparatives and timing delays (e.g., Cardiosave deliveries in CEE). The company reported SEK 824m adjusted EBITA (11.1% margin) but noted a SEK 226m negative impact from tariffs and FX; excluding those headwinds the adjusted EBITA margin would have been ~12.6%, indicating improving underlying performance. Free cash flow was strong at SEK 842m, net debt fell to SEK 9.3bn (1.5x adjusted EBITDA leverage, or 1.1x adjusted for pension liabilities), and cash on hand was ~SEK 4bn. Key operational milestones: CE approval and limited market release of Cardiohelp II (full CE release planned Q3; U.S. submission H2 2026) and EU MDR approval for Intergard Synergy. Management reiterated the 2026 organic sales guidance of +3–5% (adjusted for the Surgical Perfusion phaseout) and reaffirmed the long‑term adjusted EBITA margin target of 16–19% by end‑2028, while highlighting ongoing quality remediation, productivity efforts, and the tariff/FX uncertainty that continues to pressure near‑term margins.
